Lawrence Otto Klein Sells 1,729 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $41.30, for a total transaction of $71,407.70. Following the transaction, the chief executive officer owned 927,309 shares in the company, valued at approximately $38,297,861.70. The trade was a 0.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Oruka Therapeutics Stock Down 1.1%

Shares of ORKA traded down $0.44 during mid-day trading on Tuesday, hitting $41.31. 645,354 shares of the company’s stock were exchanged, compared to its average volume of 462,463. Oruka Therapeutics, Inc. has a 52 week low of $5.49 and a 52 week high of $42.41. The stock’s 50-day simple moving average is $33.22 and its 200-day simple moving average is $27.86. The firm has a market cap of $2.05 billion, a price-to-earnings ratio of -22.21 and a beta of -0.38.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.16. Analysts forecast that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ORKA has been the subject of a number of research analyst reports. Wall Street Zen raised Oruka Therapeutics from a “sell” rating to a “hold” rating in a report on Monday. Guggenheim reaffirmed a “buy” rating and set a $60.00 price target on shares of Oruka Therapeutics in a report on Friday. Stifel Nicolaus raised their target price on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Thursday, January 22nd. Finally, Barclays increased their price objective on shares of Oruka Therapeutics from $48.00 to $50.00 and gave the stock an “overweight” rating in a research report on Friday. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $59.60.

Trending Headlines about Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Leerink Partners raised its price target on ORKA from $58 to $86 and maintained an “outperform” rating — a large upward revision that signals strong conviction from a prominent analyst. Leerink price target raise
• Positive Sentiment: BTIG Research reiterated a Buy rating on Oruka, reinforcing institutional analyst support that can sustain buying pressure. BTIG Buy Rating Reiterated
• Positive Sentiment: Wedbush reiterated an Outperform rating and Guggenheim reiterated a Buy — multiple confirmations of bullish views from different houses increase the credibility of the upgrade trend. Wedbush Outperform Reiterated
• Positive Sentiment: Several price‑target raises have been reported (including a $50 target in one note), and Wall Street Zen upgraded ORKA — the aggregation of higher targets and upgrades is likely supporting higher valuations. Price Target Raised to $50 Wall Street Zen Upgrade
• Neutral Sentiment: Zacks highlighted that the average analyst price target implies roughly 41.5% upside for ORKA but also cautioned about the metric’s limitations — useful for gauging sentiment but not a guarantee of performance. Zacks analyst consensus piece
• Neutral Sentiment: General market/company news roundups (e.g., MSN) mentioned ORKA among recent movers but added no new company‑specific catalysts; useful for context but not a driver by itself. MSN company news

Institutional Trading of Oruka Therapeutics

Several large investors have recently modified their holdings of ORKA. Royal Bank of Canada increased its stake in shares of Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after acquiring an additional 365 shares in the last quarter. Kennedy Capital Management LLC grew its holdings in Oruka Therapeutics by 0.9% in the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock worth $1,476,000 after purchasing an additional 420 shares during the period. Russell Investments Group Ltd. grew its holdings in Oruka Therapeutics by 35.0% in the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock worth $92,000 after purchasing an additional 788 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Oruka Therapeutics by 62.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock valued at $71,000 after purchasing an additional 904 shares in the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in shares of Oruka Therapeutics during the fourth quarter valued at about $37,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.